Patents by Inventor Karen Kabat Stegman

Karen Kabat Stegman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
    Patent number: 8357533
    Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: January 22, 2013
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Zeling Cai, Ann Moriarty, Juli Degraw, Didier Leturcq, Wei-Xing Shi, Karen Kabat Stegman, Xilian Yue
  • PREPARATION OF INACTIVATED ARTIFICIAL ANTIGEN PRESENTING CELLS AND THEIR USE IN CELL THERAPIES
    Publication number: 20120115223
    Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 10, 2012
    Inventors: Zeling Cai, Ann Moriarty, Juli Degraw, Didier Leturcq, Wei-Xing Shi, Karen Kabat Stegman, Xilian Yue
  • Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
    Patent number: 8124408
    Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: February 28, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Zeling Cai, Ann Moriarty, Juli Degraw, Didier Leturcq, Wei-Xing Shi, Karen Kabat Stegman, Xilian Yue
  • Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
    Publication number: 20090017000
    Abstract: Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation.
    Type: Application
    Filed: October 4, 2007
    Publication date: January 15, 2009
    Inventors: Zeling Cai, Ann Moriarity, Juli Degraw, Didier Leturcq, Wei-Xing Shi, Karen Kabat Stegman, Xilian Yue